Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of December 2019, specifically dated December 16, 2019. The report details the entry into material definitive agreements regarding a prior private placement of senior convertible notes and warrants completed in May 2019. The filing addresses the resolution of events of default triggered in July 2019 through the execution of Forbearance and Amendment Agreements with two institutional investors.
Key Financial Metrics and Capital Structure
The filing does not provide standard operating financial metrics such as revenue, net income, operating cash flow, or gross margins. The financial data presented relates exclusively to the restructuring of debt obligations:
- Debt Instrument: Series A Senior Convertible Notes with an aggregate principal amount of $10 million.
- Initial Consideration Received (May 2019): $10 million in cash and $5 million in investor promissory notes (Series B Notes).
- Forbearance Redemption Price: The Company agreed to redeem the Series A Notes for an aggregate price of $10,939,410.21.
- Initial Forbearance Fee: $500,000 payable to each investor (total $1,000,000) by December 16, 2019.
- Redemption Schedule: Commencing January 24, 2020, with a final deadline of October 15, 2020, unless defaults occur.
Material Changes and Agreements
The primary material change is the execution of Forbearance Agreements on December 13, 2019, which altered the terms of the outstanding Series A Notes following investor notices of default. Key changes include:
- Resolution of Series B Notes: The Series B Notes, Investor Notes, and Series B Warrants were netted out and are no longer outstanding.
- Forbearance Period: Investors agreed to forbear from enforcing redemption rights regarding existing defaults and specific additional defaults (including trading volume and price thresholds) until October 15, 2020.
- Conversion Restrictions: Investors agreed not to convert Series A Notes or exercise Series A Warrants unless the trading price of ordinary shares is at least $2.50 (Forbearance Conversion Floor).
- Pre-Delivered Shares: The Company pre-delivered 4 million ordinary shares as security. Under the new agreements, these shares are subject to lock-up and leak-out restrictions, with provisions for their return upon full payment of redemption amounts.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the new agreements and standard forward-looking statement disclaimers. Significant risks and contingencies identified include:
- Liquidity Risk: The Company must meet strict installment payment deadlines starting January 24, 2020. Failure to pay within 5 days allows investors to convert the unpaid amount into shares, disregarding the conversion floor.
- Default Triggers: The forbearance period ends immediately if the Company breaches any term of the agreement or triggers a new event of default.
- Market Conditions: The agreement includes specific triggers related to the Company's stock price (failure to exceed $2.14 VWAP) and trading volume (failure to exceed $1.5 million daily), which could lead to enforcement actions if not met.
- Share Dilution: If the Company fails to deliver conversion shares, investors may apply pre-delivered shares to satisfy obligations, potentially impacting the share count and ownership structure.
Investor Verification Checklist
- Verify the Company's ability to fund the $10,939,410.21 redemption obligation and the $1,000,000 initial fee by the specified deadlines.
- Monitor the Company's daily trading volume and share price to ensure they remain above the thresholds ($1.5M volume, $2.14 price) that could trigger a breach of the forbearance agreement.
- Confirm the status of the 4 million pre-delivered shares and whether they have been returned to the Company or remain held by investors as collateral.
- Review subsequent filings for any missed installment payments that would trigger immediate conversion rights for investors.
- Assess the impact of potential share issuance upon conversion of the Series A Notes on existing shareholder dilution.